Nexus Pharmaceuticals reported on Thursday the availability of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials for the treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin.
The company added that the Erythromycin Lactobionate for Injection is available in cartons of five single-dose vials and is an AP-rated generic to ERYTHROCIN¥.
In addition, the launch of Erythromycin Lactobionate showcases the company's commitment to providing critical antibiotics where and when they are needed most, said Vince LoPiccolo, VP of Sales and Marketing.
Based in the US, the healthcare company specialises in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling